Dr. Peter Michael, M.D.
Pain Medicine (Pain Medicine (Physical Medicine & Rehabilitation) Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 47
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Miami, Lm Miller School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pain Medicine (Physical Medicine & Rehabilitation) Physician primary
FL license ME127046 -
Physical Medicine & Rehabilitation Physician
FL license ME127046
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Homestead Hospital Homestead, FL
Medical groups
- Matmed LLC (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 47
- Services billed
- 260
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Coral Gables, FL | 1,791 |
| Celecoxib Other prescribers in Coral Gables, FL | 651 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Coral Gables, FL | 601 |
| Tramadol Hcl Other prescribers in Coral Gables, FL | 544 |
| Diclofenac Sodium Other prescribers in Coral Gables, FL | 371 |
| Meloxicam Other prescribers in Coral Gables, FL | 352 |
| Acetaminophen-Codeine (acetaminophen with codeine) Other prescribers in Coral Gables, FL | 307 |
| Tramadol Hcl-Acetaminophen (tramadol hcl/acetaminophen) Other prescribers in Coral Gables, FL | 210 |
| Pregabalin Other prescribers in Coral Gables, FL | 193 |
| Baclofen Other prescribers in Coral Gables, FL | 168 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $102,932 in research payments for these studies, mostly to the institutions running them.
- Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie Inc. · Completed · NCT04578756 - Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder
AbbVie Inc. - SUBLOCADE Long-term Outcomes
Indivior Inc. · Completed · NCT05860959 - A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder
AbbVie Inc. - M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
AbbVie Inc. - A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie Inc. · Recruiting · NCT04777357
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.